Search

Your search keyword '"McAleenan, Alexandra"' showing total 45 results
Start Over Author "McAleenan, Alexandra"
45 results on '"McAleenan, Alexandra"'

1. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)

Author

Higgins, Julian P.T., Morgan, Rebecca L., Rooney, Andrew A., Taylor, Kyla W., Thayer, Kristina A., Silva, Raquel A., Lemeris, Courtney, Akl, Elie A., Bateson, Thomas F., Berkman, Nancy D., Glenn, Barbara S., Hróbjartsson, Asbjørn, LaKind, Judy S., McAleenan, Alexandra, Meerpohl, Joerg J., Nachman, Rebecca M., Obbagy, Julie E., O'Connor, Annette, Radke, Elizabeth G., Savović, Jelena, Schünemann, Holger J., Shea, Beverley, Tilling, Kate, Verbeek, Jos, Viswanathan, Meera, and Sterne, Jonathan A.C.

Published
2024
Full Text
View/download PDF

2. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies

Author

Cheng, Hung-Yuan, French, Clare E., Salam, Alex P., Dawson, Sarah, McAleenan, Alexandra, McGuinness, Luke A., Savovic, Jelena, Horby, Peter W., and Sterne, Jonathan A.C.

Subjects
Ribavirin -- Dosage and administration -- Patient outcomes, Lassa fever -- Care and treatment -- Diagnosis, Health
Abstract

Lassa virus infection, first described in 1962, is a viral hemorrhagic fever (1). It is a substantial public health burden, causing an estimated 100,000-200,000 cases each year, mainly in West [...]

Published
2022
Full Text
View/download PDF

5. RoB 2 : a revised tool for assessing risk of bias in randomised trials

Author

Sterne, Jonathan A C, Savović, Jelena, Page, Matthew J, Elbers, Roy G, Blencowe, Natalie S, Boutron, Isabelle, Cates, Christopher J, Cheng, Hung-Yuan, Corbett, Mark S, Eldridge, Sandra M, Emberson, Jonathan R, Hernán, Miguel A, Hopewell, Sally, Hróbjartsson, Asbjorn, Junqueira, Daniela R, Jüni, Peter, Kirkham, Jamie J, Lasserson, Toby, Li, Tianjing, McAleenan, Alexandra, Reeves, Barnaby C, Shepperd, Sasha, Shrier, Ian, Stewart, Lesley A, Tilling, Kate, White, Ian R, Whiting, Penny F, and Higgins, Julian P T

Published
2019

6. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms : A White Paper From COMBACTE’s STAT-Net

Author

COMBACTE-NET Consortium, de Kraker, Marlieke E. A., Sommer, Harriet, de Velde, Femke, Gravestock, Isaac, Weiss, Emmanuel, McAleenan, Alexandra, Nikolakopoulos, Stavros, Amit, Ohad, Ashton, Teri, Beyersmann, Jan, Held, Leonhard, Lovering, Andrew M., MacGowan, Alasdair P., Mouton, Johan W., Timsit, Jean-François, Wilson, David, Wolkewitz, Martin, Bettiol, Esther, Dane, Aaron, and Harbarth, Stephan

Published
2018

7. DNA damage provokes cohesin sumoylation in Saccharomyces cerevisiae

Author

McAleenan, Alexandra Susan Jane and Aragon, Luis

Subjects
571.6
Abstract

Cohesin tethers sister chromatids together from their creation during S-phase until their separation at the metaphase to anaphase transition. Cohesion is essential for correct segregation and therefore genomic stability. Cohesin is also involved the regulation of transcription and in DNA repair. Cohesin affects these processes by its ability to hold two pieces of DNA together. Cohesin is subject to a variety of post-translational modifications. In this study, the modification of cohesin, more specifically the Scc1 subunit, by Small ubiquitin-like modifier (SUMO) was analysed. It was found that cohesin is sumoylated during an unperturbed cell cycle, but is hyper-modified after DNA damage. To determine the function Scc1 modification by SUMO, attempts were made to identify the modified residues. Mass spectrometry techniques for SUMO site identification were developed in parallel to site-directed mutagenesis studies. Potential sumoylation sites were identified on Scc1, but when these were mutated there was little effect on either viability or the sumoylation pattern obtained. Mutants were then constructed in which only one lysine was present. Surprisingly, several of these were viable, not sensitive to methyl methanesulfonate and were not sumoylated, suggesting that either sumoylation of Scc1 is not essential and not required after DNA damage, or that sumoylation of the rest of the cohesin complex can compensate. To investigate this, Scc1 fusions with the SUMO E2 ligase, Ubc9, and a SUMO isopeptidase, Ulp1, to mimic constitutively sumoylated and unsumoylatable cohesin respectively, were constructed. Unexpectedly, it was found that both fusions relocalized to a double strand break, and that the Ulp1 fusion was recruited to a greater extent. Data from our laboratory suggests that the Ubc9 fusion is not competent for cohesion after damage, although it is sufficient for viability. Sumoylation may therefore be involved in cohesin unloading or turnover, which might be required after DNA damage.

Published
2010
Full Text
View/download PDF

8. Drug-Induced Permeabilization in Fungi

Author

Mayan, Maria D., McAleenan, Alexandra, Braglia, Priscilla, Gupta, Vijai Kumar, editor, Tuohy, Maria G., editor, Ayyachamy, Manimaran, editor, Turner, Kevin M., editor, and O’Donovan, Anthonia, editor

Published
2013
Full Text
View/download PDF

9. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review

Author

Brandner, Sebastian, primary, McAleenan, Alexandra, additional, Jones, Hayley E., additional, Kernohan, Ashleigh, additional, Robinson, Tomos, additional, Schmidt, Lena, additional, Dawson, Sarah, additional, Kelly, Claire, additional, Leal, Emmelyn Spencer, additional, Faulkner, Claire L., additional, Palmer, Abigail, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Vale, Luke, additional, Higgins, Julian P. T., additional, and Kurian, Kathreena M., additional

Published
2022
Full Text
View/download PDF

10. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma

Author

McAleenan, Alexandra, additional, Jones, Hayley E, additional, Kernohan, Ashleigh, additional, Robinson, Tomos, additional, Schmidt, Lena, additional, Dawson, Sarah, additional, Kelly, Claire, additional, Spencer Leal, Emmelyn, additional, Faulkner, Claire L, additional, Palmer, Abigail, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Brandner, Sebastian, additional, Vale, Luke, additional, Higgins, Julian PT, additional, and Kurian, Kathreena M, additional

Published
2022
Full Text
View/download PDF

11. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review

Author

Andrews, Lily J, primary, Thornton, Zak A, additional, Saincher, Saanwalshah S, additional, Yao, Ian Y, additional, Dawson, Sarah, additional, McGuinness, Luke A, additional, Jones, Hayley E, additional, Jefferies, Sarah, additional, Short, Susan C, additional, Cheng, Hung-Yuan, additional, McAleenan, Alexandra, additional, Higgins, Julian P T, additional, and Kurian, Kathreena M, additional

Published
2021
Full Text
View/download PDF

13. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1.

Author

Hung-Yuan Cheng, French, Clare E., Salam, Alex P., Dawson, Sarah, McAleenan, Alexandra, McGuinness, Luke A., Savović, Jelena, Horby, Peter W., Sterne, Jonathan A. C., and Cheng, Hung-Yuan

Subjects
RIBAVIRIN, RESEARCH funding, RNA viruses
Abstract

Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use. We conducted a systematic review of published and unpublished literature retrieved from electronic databases and gray literature from inception to March 8, 2022. We identified 13 studies of the comparative effectiveness of ribavirin versus no ribavirin treatment on mortality outcomes, including unpublished data from a study in Sierra Leone provided through a US Freedom of Information Act request. Although ribavirin was associated with decreased mortality rates, results of these studies were at critical or serious risk for bias when appraised using the ROBINS-I tool. Important risks for bias related to lack of control for confounders, immortal time bias, and missing outcome data. Robust evidence supporting the use of ribavirin in Lassa fever is lacking. Well-conducted clinical trials to elucidate the effectiveness of ribavirin for Lassa fever are needed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Post-replicative repair involves separase-dependent removal of the kleisin subunit of cohesin

Author

McAleenan, Alexandra, Clemente-Blanco, Andres, Cordon-Preciado, Violeta, Sen, Nicholas, Esteras, Miguel, Jarmuz, Adam, and Aragon, Luis

Subjects
DNA repair -- Research, Cysteine proteinases -- Physiological aspects -- Research, Cellular proteins -- Physiological aspects -- Research -- Genetic aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

DNA double-strand break repair is critical for cell viability and involves highly coordinated pathways to restore DNA integrity at the lesion. An early event during homology-dependent repair is resection of [...]

Published
2013

16. MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review

Author

Brandner, Sebastian, primary, McAleenan, Alexandra, additional, Kelly, Claire, additional, Spiga, Francesca, additional, Cheng, Hung-Yuan, additional, Dawson, Sarah, additional, Schmidt, Lena, additional, Faulkner, Claire L, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Higgins, Julian P T, additional, and Kurian, Kathreena M, additional

Published
2021
Full Text
View/download PDF

18. Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

Author

McAleenan, Alexandra, additional, Kelly, Claire, additional, Spiga, Francesca, additional, Kernohan, Ashleigh, additional, Cheng, Hung-Yuan, additional, Dawson, Sarah, additional, Schmidt, Lena, additional, Robinson, Tomos, additional, Brandner, Sebastian, additional, Faulkner, Claire L, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Howell, Amy, additional, Vale, Luke, additional, Higgins, Julian P T, additional, and Kurian, Kathreena M, additional

Published
2021
Full Text
View/download PDF

27. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma

Author

McAleenan, Alexandra, primary, Jones, Hayley E, additional, Kernohan, Ashleigh, additional, Faulkner, Claire L, additional, Palmer, Abigail, additional, Dawson, Sarah, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Brandner, Sebastian, additional, Vale, Luke, additional, Higgins, Julian P T, additional, and Kurian, Kathreena M, additional

Published
2019
Full Text
View/download PDF

28. Prognostic value of test(s) for O6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

Author

McAleenan, Alexandra, primary, Howell, Amy, additional, Kernohan, Ashleigh, additional, Faulkner, Claire L, additional, Dawson, Sarah, additional, Wragg, Christopher, additional, Jefferies, Sarah, additional, Brandner, Sebastian, additional, Vale, Luke, additional, Higgins, Julian P T, additional, and Kurian, Kathreena M, additional

Published
2019
Full Text
View/download PDF

32. Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis.

Author

Hung-Yuan Cheng, McGuinness, Luke A., Elbers, Roy G., MacArthur, Georgina J., Taylor, Abigail, McAleenan, Alexandra, Dawson, Sarah, López-López, José A., Higgins, Julian P. T., Cowlishaw, Sean, Lingford-Hughes, Anne, Hickman, Matthew, and Kessler, David

Subjects
REHABILITATION of people with alcoholism, CONFIDENCE intervals, ALCOHOL drinking, INFORMATION storage & retrieval systems, MEDICAL databases, MEDICAL information storage & retrieval systems, MEDLINE, META-analysis, PRIMARY health care, SYSTEMATIC reviews
Published
2020
Full Text
View/download PDF

33. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis

Author

Welton, Nicky J, primary, McAleenan, Alexandra, additional, Thom, Howard HZ, additional, Davies, Philippa, additional, Hollingworth, Will, additional, Higgins, Julian PT, additional, Okoli, George, additional, Sterne, Jonathan AC, additional, Feder, Gene, additional, Eaton, Diane, additional, Hingorani, Aroon, additional, Fawsitt, Christopher, additional, Lobban, Trudie, additional, Bryden, Peter, additional, Richards, Alison, additional, and Sofat, Reecha, additional

Published
2017
Full Text
View/download PDF

34. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Author

Kraker, Marlieke E A de, Sommer, Harriet, Velde, Femke de, Gravestock, Isaac, Weiss, Emmanuel, McAleenan, Alexandra, Nikolakopoulos, Stavros, Amit, Ohad, Ashton, Teri, and Beyersmann, Jan

Subjects
ANTIBIOTICS, CLINICAL trials, EXPERIMENTAL design, MEDICAL protocols, MULTIDRUG resistance, PUBLIC health, QUALITY assurance, EVIDENCE-based medicine, PHARMACODYNAMICS
Abstract

Innovations are urgently required for clinical development of antibacterials against multidrug-resistant organisms. Therefore, a European, public-private working group (STAT-Net; part of Combatting Bacterial Resistance in Europe [COMBACTE]), has reviewed and tested several innovative trials designs and analytical methods for randomized clinical trials, which has resulted in 8 recommendations. The first 3 focus on pharmacokinetic and pharmacodynamic modeling, emphasizing the pertinence of population-based pharmacokinetic models, regulatory procedures for the reassessment of old antibiotics, and rigorous quality improvement. Recommendations 4 and 5 address the need for more sensitive primary end points through the use of rank-based or time-dependent composite end points. Recommendation 6 relates to the applicability of hierarchical nested-trial designs, and the last 2 recommendations propose the incorporation of historical or concomitant trial data through Bayesian methods and/or platform trials. Although not all of these recommendations are directly applicable, they provide a solid, evidence-based approach to develop new, and established, antibacterials and address this public health challenge. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. Use of Mendelian R andomization for I dentifying R isk F actors for B rain T umors.

Author

Howell, Amy Elizabeth, Zheng, Jie, Haycock, Philip C., McAleenan, Alexandra, Relton, Caroline, Martin, Richard M., and Kurian, Kathreena M.

Abstract

Gliomas are a group of primary brain tumors, the most common and aggressive subtype of which is glioblastoma. Glioblastoma has a median survival of just 15 months after diagnosis. Only previous exposure to ionizing radiation and particular inherited genetic syndromes are accepted risk factors for glioma; the vast majority of cases are thought to occur spontaneously. Previous observational studies have described associations between several risk factors and glioma, but studies are often conflicting and whether these associations reflect true casual relationships is unclear because observational studies may be susceptible to confounding, measurement error and reverse causation. Mendelian randomization (MR) is a form of instrumental variable analysis that can be used to provide supporting evidence for causal relationships between exposures (e.g., risk factors) and outcomes (e.g., disease onset). MR utilizes genetic variants, such as single nucleotide polymorphisms (SNPs), that are robustly associated with an exposure to determine whether there is a causal effect of the exposure on the outcome. MR is less susceptible to confounding, reverse causation and measurement errors as it is based on the random inheritance during conception of genetic variants that can be relatively accurately measured. In previous studies, MR has implicated a genetically predicted increase in telomere length with an increased risk of glioma, and found little evidence that obesity related factors, vitamin D or atopy are causal in glioma risk. In this review, we describe MR and its potential use to discover and validate novel risk factors, mechanistic factors, and therapeutic targets in glioma. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

39. Smc5–Smc6 mediate DNA double-strand-break repair by promoting sister-chromatid recombination

Author

De Piccoli, Giacomo, primary, Cortes-Ledesma, Felipe, additional, Ira, Gregory, additional, Torres-Rosell, Jordi, additional, Uhle, Stefan, additional, Farmer, Sarah, additional, Hwang, Ji-Young, additional, Machin, Felix, additional, Ceschia, Audrey, additional, McAleenan, Alexandra, additional, Cordon-Preciado, Violeta, additional, Clemente-Blanco, Andrés, additional, Vilella-Mitjana, Felip, additional, Ullal, Pranav, additional, Jarmuz, Adam, additional, Leitao, Beatriz, additional, Bressan, Debra, additional, Dotiwala, Farokh, additional, Papusha, Alma, additional, Zhao, Xiaolan, additional, Myung, Kyungjae, additional, Haber, James E., additional, Aguilera, Andrés, additional, and Aragón, Luis, additional

Published
2006
Full Text
View/download PDF

41. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE’s STAT-Net

Author

de Kraker, Marlieke E A, Sommer, Harriet, de Velde, Femke, Gravestock, Isaac, Weiss, Emmanuel, McAleenan, Alexandra, Nikolakopoulos, Stavros, Amit, Ohad, Ashton, Teri, Beyersmann, Jan, Held, Leonhard, Lovering, Andrew M, MacGowan, Alasdair P, Mouton, Johan W, Timsit, Jean-François, Wilson, David, Wolkewitz, Martin, Bettiol, Esther, Dane, Aaron, and Harbarth, Stephan

Subjects
3. Good health

44. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1.

Author

Hung-Yuan Cheng, French, Clare E., Salam, Alex P., Dawson, Sarah, McAleenan, Alexandra, McGuinness, Luke A., Savović, Jelena, Horby, Peter W., Sterne, Jonathan A. C., and Cheng, Hung-Yuan

Subjects
*RIBAVIRIN, *RESEARCH funding, *RNA viruses
Abstract

Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use. We conducted a systematic review of published and unpublished literature retrieved from electronic databases and gray literature from inception to March 8, 2022. We identified 13 studies of the comparative effectiveness of ribavirin versus no ribavirin treatment on mortality outcomes, including unpublished data from a study in Sierra Leone provided through a US Freedom of Information Act request. Although ribavirin was associated with decreased mortality rates, results of these studies were at critical or serious risk for bias when appraised using the ROBINS-I tool. Important risks for bias related to lack of control for confounders, immortal time bias, and missing outcome data. Robust evidence supporting the use of ribavirin in Lassa fever is lacking. Well-conducted clinical trials to elucidate the effectiveness of ribavirin for Lassa fever are needed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Author

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, and Harbarth S

Subjects
Anti-Bacterial Agents therapeutic use, Bacterial Infections drug therapy, Bayes Theorem, Data Interpretation, Statistical, Evidence-Based Medicine, Humans, Anti-Bacterial Agents pharmacokinetics, Drug Resistance, Multiple, Bacterial, Randomized Controlled Trials as Topic, Research Design standards
Abstract

Innovations are urgently required for clinical development of antibacterials against multidrug-resistant organisms. Therefore, a European, public-private working group (STAT-Net; part of Combatting Bacterial Resistance in Europe [COMBACTE]), has reviewed and tested several innovative trials designs and analytical methods for randomized clinical trials, which has resulted in 8 recommendations. The first 3 focus on pharmacokinetic and pharmacodynamic modeling, emphasizing the pertinence of population-based pharmacokinetic models, regulatory procedures for the reassessment of old antibiotics, and rigorous quality improvement. Recommendations 4 and 5 address the need for more sensitive primary end points through the use of rank-based or time-dependent composite end points. Recommendation 6 relates to the applicability of hierarchical nested-trial designs, and the last 2 recommendations propose the incorporation of historical or concomitant trial data through Bayesian methods and/or platform trials. Although not all of these recommendations are directly applicable, they provide a solid, evidence-based approach to develop new, and established, antibacterials and address this public health challenge.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results